Combined anti-vascular later-line therapy

52% longer median PFS

Adding anti-vascular therapy to chemotherapy offers a clear survival benefit for patients with malignant pleural mesothelioma in later-line treatment.

Keda, Shao · Wang, Qian · Wang, Dong · Yue, Hao · Li, Bihui · Huang, Jianhui · Wu, Jingxun · Huang, Long · Li, Wenfeng · Meng, Rui · Feng, Jian · Fu, Jianfei · Feng, Huijing · Xu, Ling · Shi, Xuefei · Song, Zhengbo

Journal of Thoracic Disease 2025

Specifications

PFS months vs

{'zh': '', 'en': '3.00'} months

OS months vs

{'zh': '', 'en': '10.03'} months

Advantages

85 patients with MPM who failed first-line treatment were included